Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers to Use PPGx Software

NEW YORK, Oct 6 - PPGx of Morrisville, NC, said Friday that Bristol-Myers Sqibb (NYSE: BMY) has signed on for early access to its GeneTrial software for pharmacogenomics research.

The GeneTrials platform is designed to manage the vast amount of publicly available and in-house clinical and genomic data.

Included in the software package is the GeneTrials Data Warehouse, an Oracle-based repository that uses sophisticated commercial data warehousing technology to integrate, manage, and organize pharmacogenomic data, and the GeneTrials Explorer, a user interface for browsing, querying, annotating, and analyzing information stored within the GeneTrials Data Warehouse.

“As we lead research into the era of personalized medicine, the ability to integrate research data across a variety of disciplines becomes a critical capability,” said Nicholas Dracopoli, executive director of pharmacogenomics at Bristol-Myers Squibb.

Financial terms of the deal were not disclosed.

The agreement, however, underscores the fact that providing shrink-wrapped software might not cut it anymore. PPGx will customize the software for the pharmaceutical company’s specific project needs and will also act as a pharmacogenomics consultant.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.